Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Trifluridine-tipiracil (Lonsurf) for refractory metastatic colorectal cancer. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' conclusions Description of Technology: This report focuses on the use of the trifluridine (TFD) and tipiracil hydrochloride (TPI) combination (Lonsurf; previously called TAS-102) for the treatment of refractory metastatic colorectal cancer (CRC). TFD is an antineoplastic thymidine-based nucleoside analog that acts as a nucleoside metabolic inhibitor, and TPI is a thymidine phosphorylase inhibitor. The combination agent is administered orally.
Patient Population: TFD-TPI is used to treat adult patients with metastatic CRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) biological therapy, and, if RAS (KRAS, HRAS, NRAS) wild-type, an anti-epidermal growth factor receptor (EGFR) therapy. Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Trifluridine Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32016000797 Date abstract record published 15/06/2016 |